CYSLTR1 binds CYSLTR1 antagonists

Jassal, B., Shoichet, BK.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

02/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics, 18*, 142. ↗

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics, 33*, 3461-3467. ↗

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655. ↗

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology, 14*, e1005968. ↗

CYSLTR1 binds CYSLTR1 antagonists ↗

Stable identifier: R-HSA-9684627

Type: binding

Compartments: extracellular region, plasma membrane



Cysteinyl leukotriene receptor 1 (CYSLTR1) is a GPCR through which leukotriene D4 mediates bronchoconstriction. CYSLTR1 antagonists work by antagonising the effects of proinflammatory leukotrienes (such as LTC4, LTD4 and LTE4), resulting in decreased inflammation and decreased hyperresponsiveness of airways to immune challenges (Capra et al. 1998, Snyder & Fleisch 1989, Wendell et al. 2020). The CYSLTR1 antagonists listed here comprise approved (montelukast, pranlukast and zafirlukast) and investigational drugs used in asthma therapy.

Literature references

Snyder, DW., Fleisch, JH. (1989). Leukotriene receptor antagonists as potential therapeutic agents. *Annu. Rev. Pharmacol. Toxicol., 29*, 123-43. ↗

Bolla, M., Mezzetti, M., Nicosia, S., Belloni, PA., Folco, GC., Capra, V. et al. (1998). Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. *Br. J. Pharmacol., 123*, 590-8. ↗

Editions

2020-04-21	Authored, Edited	Jassal, B.
2020-05-14	Reviewed	Shoichet, BK.